Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) EBT: 2010-2025

Historic EBT for Iovance Biotherapeutics (IOVA) over the last 9 years, with Sep 2025 value amounting to -$93.7 million.

  • Iovance Biotherapeutics' EBT fell 10.11% to -$93.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$398.3 million, marking a year-over-year increase of 4.28%. This contributed to the annual value of -$375.0 million for FY2024, which is 16.20% up from last year.
  • Iovance Biotherapeutics' EBT amounted to -$93.7 million in Q3 2025, which was up 14.60% from -$109.7 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' EBT ranged from a high of -$77.0 million in Q4 2024 and a low of -$118.1 million during Q4 2023.
  • Moreover, its 3-year median value for EBT was -$107.4 million (2023), whereas its average is -$104.0 million.
  • In the last 5 years, Iovance Biotherapeutics' EBT soared by 34.82% in 2024 and then declined by 11.27% in 2025.
  • Quarterly analysis of 3 years shows Iovance Biotherapeutics' EBT stood at -$118.1 million in 2023, then soared by 34.82% to -$77.0 million in 2024, then fell by 10.11% to -$93.7 million in 2025.
  • Its EBT stands at -$93.7 million for Q3 2025, versus -$109.7 million for Q2 2025 and -$118.0 million for Q1 2025.